Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

United Therapeutic (UTHR)

United Therapeutic (UTHR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,267,998
  • Shares Outstanding, K 44,796
  • Annual Sales, $ 1,483 M
  • Annual Income, $ 514,800 K
  • 60-Month Beta 0.49
  • Price/Sales 5.61
  • Price/Cash Flow 14.62
  • Price/Book 2.42
Trade UTHR with:

Options Overview

Details
  • Implied Volatility 37.31%
  • Historical Volatility 18.96%
  • IV Percentile 52%
  • IV Rank 36.38%
  • IV High 51.09% on 02/18/21
  • IV Low 29.42% on 06/24/21
  • Put/Call Vol Ratio 0.22
  • Today's Volume 11
  • Volume Avg (30-Day) 48
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 5,019
  • Open Int (30-Day) 5,849

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 2.86
  • Number of Estimates 4
  • High Estimate 3.00
  • Low Estimate 2.63
  • Prior Year 2.41
  • Growth Rate Est. (year over year) +18.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
174.46 +5.05%
on 06/28/21
188.63 -2.84%
on 07/09/21
+3.27 (+1.82%)
since 06/25/21
3-Month
170.06 +7.77%
on 06/08/21
208.96 -12.29%
on 04/27/21
-24.84 (-11.94%)
since 04/26/21
52-Week
98.37 +86.31%
on 09/24/20
212.62 -13.80%
on 04/22/21
+71.01 (+63.25%)
since 07/24/20

Most Recent Stories

More News
3 Undervalued Biotech Stocks to Watch in July

Because the spread of the coronavirus Delta variant in several countries is becoming a major concern, the biotech industry is expected to continue attracting investors’ attention. The industry’s role...

UTHR : 183.27 (-0.70%)
SIGA : 6.07 (+0.33%)
OVID : 3.71 (-0.80%)
$7.85 Billion Pulmonary Arterial Hypertension Global Market to 2026 - Featuring Gilead Sciences, United Therapeutics and Novartis International Among Others - ResearchAndMarkets.com

The "Global Pulmonary Arterial Hypertension Market (2021-2026) by Drug Class, Route of Administration, Distribution Mode, Geography, Competitive Analysis and the Impact of COVID-19 with Ansoff Analysis"...

GILD : 68.75 (-0.39%)
UTHR : 183.27 (-0.70%)
United Therapeutics Announces The Lancet Respiratory Medicine Publication Of Post-Hoc Analysis Of FVC Change From The Tyvaso® INCREASE Study

and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced the in of a post-hoc analysis of forced vital capacity () change in patients during the study of Tyvaso® (treprostinil)...

UTHR : 183.27 (-0.70%)
3D Systems (DDD) Joins CollPlant for Bioprinted Breast Tissue Matrix

The collaborative efforts of 3D Systems (DDD) and CollPlant aim to eliminate the odds of adverse immune response in the human body induced by procedures using tissue derived from humans and animals.

UTHR : 183.27 (-0.70%)
DDD : 24.82 (-3.87%)
SIMO : 61.58 (-0.66%)
CLGN : 17.94 (+1.30%)
United Therapeutics (UTHR) Tyvaso DPI Gets FDA's Priority Tag

United Therapeutics' (UTHR) Tyvaso DPI is a drug device combination therapy, comprising the dry powder formulation of Tyvaso and a small, portable, dry powder inhaler.

MNKD : 4.38 (+0.23%)
LLY : 243.21 (-0.39%)
UTHR : 183.27 (-0.70%)
CPIX : 3.28 (+0.61%)
MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI™ With New Drug Application Acceptance From The FDA

/PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) and United Therapeutics Corporation (Nasdaq: UTHR) reached a major milestone today with the announcement that the U.S. Food and Drug Administration (FDA)...

UTHR : 183.27 (-0.70%)
MNKD : 4.38 (+0.23%)
United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review

and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration () accepted for priority review the New Drug Application () for Tyvaso DPI™...

UTHR : 183.27 (-0.70%)
MNKD : 4.38 (+0.23%)
United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia

and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is pursuing additional claims for trade secret misappropriation against Liquidia Technologies, Inc. (a subsidiary...

LQDA : 2.44 (-0.81%)
UTHR : 183.27 (-0.70%)
Why Is United Therapeutics (UTHR) Down 8.8% Since Last Earnings Report?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

UTHR : 183.27 (-0.70%)
United Therapeutics (UTHR) Begins TETON Study on Tyvaso in IPF

United Therapeutics (UTHR) enrolls the first patient in the phase III TETON study evaluating Tyvaso for treating adult patients with idiopathic pulmonary fibrosis.

LLY : 243.21 (-0.39%)
UTHR : 183.27 (-0.70%)
XNCR : 31.36 (-1.57%)
CTLT : 113.00 (-2.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability....

See More

Key Turning Points

3rd Resistance Point 188.51
2nd Resistance Point 187.11
1st Resistance Point 185.19
Last Price 183.27
1st Support Level 181.87
2nd Support Level 180.46
3rd Support Level 178.54

See More

52-Week High 212.62
Last Price 183.27
Fibonacci 61.8% 168.98
Fibonacci 50% 155.49
Fibonacci 38.2% 142.01
52-Week Low 98.37

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar